From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
The standard dose of Incruse Ellipta (umeclidinium) is one inhalation (62.5 mcg) once daily, and this dosing frequency should not be increased. Incruse Ellipta is a long-acting muscarinic antagonist (LAMA) bronchodilator designed to provide 24-hour coverage with a single daily dose. Taking more than the prescribed dose will not provide additional benefit but may increase the risk of side effects such as dry mouth, constipation, urinary retention, and potentially cardiovascular effects. The medication works by blocking muscarinic receptors in the airways, which helps prevent bronchoconstriction and reduces symptoms of COPD.
Key Points to Consider
- The most recent and highest quality study 1 supports the use of umeclidinium as part of a triple therapy regimen, but does not suggest increasing the dose of umeclidinium itself.
- Studies have shown that adding umeclidinium to inhaled corticosteroid/long-acting β2-agonist therapy can improve lung function and reduce exacerbations in patients with COPD 2, 3.
- Increasing the dose of Incruse Ellipta is not recommended, as it may increase the risk of side effects without providing additional benefit.
- If you feel your current dose is not adequately controlling your symptoms, you should consult with your healthcare provider who might consider adding another medication from a different class (such as a long-acting beta-agonist or inhaled corticosteroid) rather than increasing the Incruse Ellipta dose.
Important Considerations
- Never adjust the dose or frequency of any inhaler without medical supervision.
- The use of umeclidinium as part of a treatment regimen for COPD should be based on individual patient needs and medical history, as determined by a healthcare provider.
- The evidence supports the use of umeclidinium at the standard dose of 62.5 mcg once daily, and increasing the dose is not recommended 4, 5.